Monoclonal Gammopathy of Undetermined SignificanceMAGICNCT06472830
MGUS/MM Awareness and Genetics Insights Campaign (MAGIC) Screening Study
An observational study of Monoclonal Gammopathy of Undetermined Significance, run by Mayo Clinic at 1 site in United States.
Trial summary
This study is being done to screen adults for MGUS and to better understand the genetic and immune factors linked to this condition. Monoclonal gammopathy of undetermined significance or MGUS is a condition where an abnormal immune protein is found in the blood. MGUS is not cancer. Read more about this study
- Who is it for?
- Ages 40 years and olderHealthy volunteers can take part
- Conditions the study is for
- Monoclonal Gammopathy of Undetermined Significance
- What is being tested?
- Non-Interventional Study
- How many people
- 1,000 participants
- Where
- 1 siteUnited States
- Study dates
- 22 May 2024to 31 May 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adults attending primary care clinics at Mayo Clinic and Mayo Clinic Health Systems, or health fairs and events
Who may be able to join
- Adults ≥ 40 years
- Willing and able to review, understand, and provide consent before starting any study-specific procedures
- Ability to complete questionnaire(s) by themselves or with assistance
Who cannot join
- Pregnant women
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Mayo Clinic in Rochester
Rochester, Minnesota, 55905
About this study
Official title: Monoclonal Gammopathy of Undetermined Significance (MGUS) /Myeloma Awareness and Genetic Insights Campaign (MAGIC) Screening Study
This study is being done to screen adults for MGUS and to better understand the genetic and immune factors linked to this condition. Monoclonal gammopathy of undetermined significance or MGUS is a condition where an abnormal immune protein is found in the blood. MGUS is not cancer. In some people, it slowly develops into a blood cancer called multiple myeloma. MGUS occurs in people from all backgrounds. Researchers hope to use the information from this study to improve knowledge, early detection, and future care for everyone.
Read the detailed description
PRIMARY OBJECTIVE:
- To determine the prevalence of monoclonal gammopathies (MGUS, Smoldering and Multiple Myeloma) across ancestrally diverse populations in Minnesota, with prespecified, ancestry-informed analyses within East African, West African, Afro-Caribbean, and Non-Hispanic White groups.
OUTLINE: This is an observational study.
Participants undergo medical chart review and blood sample collection, as well as complete a questionnaire on study. Participants who test positive for MGUS are notified, along with their primary care physician, so that the necessary follow up and referral is provided as clinically indicated.
- Being tested
- Non-Interventional Study
- Medical subject headings
- Monoclonal Gammopathy of Undetermined Significance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Non-Interventional StudyOther
Non-interventional study
| Study group | Role | What they receive |
|---|---|---|
| Observational | Participants undergo medical chart review and blood sample collection, as well as complete a questionnaire on study. Participants who test positive for MGUS are notified, along with their primary care physician, so that the necessary follow up and referral is provided as clinically indicated. Receives: Other: Non-Interventional Study |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of monoclonal gammopathies across ancestrally diverse populations
Screen for monoclonal gammopathies using mass spectrometry to detect monoclonal proteins among people across ancestrally diverse populations in Minnesota, with prespecified, ancestry-informed analyses within East African, West African, Afro-Caribbean, and Non-Hispanic White groups.
Measured: Up to 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2024
- Study start22 May 2024
- Primary completion31 May 2029 (estimated)
- Study completion31 May 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Monoclonal Gammopathy of Undetermined SignificanceStudies of the same condition, open and under way.
- More trials run by Mayo ClinicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mayo Clinic
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Joselle M. Cook, M.B.B.S., Principal investigator, Mayo Clinic in Rochester
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06472830
- Sponsor's protocol ID
- 23-008956
- Acronym
- MAGIC
- Status last verified
- Aug 2026
- First submitted
- 19 Jun 2024
- Last updated
- 11 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Monoclonal Gammopathy of Undetermined Significance (MGUS) /Myeloma Awareness and Genetic Insights Campaign (MAGIC) Screening Study
- ClinicalTrials.gov ID
- NCT06472830
- Acronym / sponsor ID
- MAGIC / 23-008956
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Mayo ClinicUniversity, hospital or other
- Study start
- 22 May 2024 (actual)
- Primary completion
- 31 May 2029 (estimated)
- Study completion
- 31 May 2029 (estimated)
- First posted
- 25 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is being done to screen adults for MGUS and to better understand the genetic and immune factors linked to this condition. Monoclonal gammopathy of undetermined significance or MGUS is a condition where an abnormal immune protein is found in the blood. MGUS is not cancer. In some people, it slowly develops into a blood cancer called multiple myeloma. MGUS occurs in people from all backgrounds. Researchers hope to use the information from this study to improve knowledge, early detection, and future care for everyone.
Detailed description
PRIMARY OBJECTIVE:
- To determine the prevalence of monoclonal gammopathies (MGUS, Smoldering and Multiple Myeloma) across ancestrally diverse populations in Minnesota, with prespecified, ancestry-informed analyses within East African, West African, Afro-Caribbean, and Non-Hispanic White groups.
OUTLINE: This is an observational study.
Participants undergo medical chart review and blood sample collection, as well as complete a questionnaire on study. Participants who test positive for MGUS are notified, along with their primary care physician, so that the necessary follow up and referral is provided as clinically indicated.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Observational | – | Other: Non-Interventional StudyParticipants undergo medical chart review and blood sample collection, as well as complete a questionnaire on study. Participants who test positive for MGUS are notified, along with their primary care physician, so that the necessary follow up and referral is provided as clinically indicated. |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adults attending primary care clinics at Mayo Clinic and Mayo Clinic Health Systems, or health fairs and events
Key inclusion criteria (3 listed)
- Adults ≥ 40 years
- Willing and able to review, understand, and provide consent before starting any study-specific procedures
- Ability to complete questionnaire(s) by themselves or with assistance
Key exclusion criteria (1 listed)
- Pregnant women
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Non-Interventional StudyNon-interventional study | Other | Observational |
Primary outcome
Prevalence of monoclonal gammopathies across ancestrally diverse populations
Time frame: Up to 10 years
Screen for monoclonal gammopathies using mass spectrometry to detect monoclonal proteins among people across ancestrally diverse populations in Minnesota, with prespecified, ancestry-informed analyses within East African, West African, Afro-Caribbean, and Non-Hispanic White groups.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Aug 2026.
- Mayo Clinic Clinical TrialsLink provided by the sponsor.
Related trials for Monoclonal Gammopathy of Undetermined Significance
RecruitingObservational study
The Indiana Myeloma Registry
Plasma Cell Dyscrasias
RecruitingObservational study
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
Monoclonal Gammopathy of Undetermined Significance, Smoldering Plasma Cell Myeloma
RecruitingObservational study
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
Monoclonal Gammopathy of Undetermined Significance, Smoldering Plasma Cell Myeloma
Recruiting
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
Multiple Myeloma, Smoldering, Multiple Myeloma
Active, not recruiting
A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Joselle M. Cook, M.B.B.S. principal investigator
Mayo Clinic in Rochester
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Monoclonal Gammopathy of Undetermined Significance, run by Mayo Clinic at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 11 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of monoclonal gammopathies across ancestrally diverse populations (time frame: Up to 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2026; AzTrials last refreshed its copy on 6 Nov 2026.